The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles
Display Omitted
Gespeichert in:
| Autor*in: |
Zhu, Zhihong [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
13 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China - Deng, Lixing ELSEVIER, 2022, the official journal of the Italian Pharmacological Society, London |
|---|---|
| Übergeordnetes Werk: |
volume:126 ; year:2017 ; pages:84-96 ; extent:13 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.phrs.2017.07.011 |
|---|
| Katalog-ID: |
ELV041064291 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV041064291 | ||
| 003 | DE-627 | ||
| 005 | 20230624082142.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180725s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phrs.2017.07.011 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000037.pica |
| 035 | |a (DE-627)ELV041064291 | ||
| 035 | |a (ELSEVIER)S1043-6618(17)30207-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 330 |q VZ |
| 100 | 1 | |a Zhu, Zhihong |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles |
| 264 | 1 | |c 2017 | |
| 300 | |a 13 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Display Omitted | ||
| 650 | 7 | |a Chemotherapy |2 Elsevier | |
| 650 | 7 | |a Docetaxel |2 Elsevier | |
| 650 | 7 | |a Endocrine therapy |2 Elsevier | |
| 650 | 7 | |a Nanoparticle drug delivery |2 Elsevier | |
| 650 | 7 | |a Combination therapy |2 Elsevier | |
| 650 | 7 | |a Tamoxifen |2 Elsevier | |
| 700 | 1 | |a Li, Yuenan |4 oth | |
| 700 | 1 | |a Yang, Xinggang |4 oth | |
| 700 | 1 | |a Pan, Weisan |4 oth | |
| 700 | 1 | |a Pan, Hao |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Academic Press |a Deng, Lixing ELSEVIER |t Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China |d 2022 |d the official journal of the Italian Pharmacological Society |g London |w (DE-627)ELV008224951 |
| 773 | 1 | 8 | |g volume:126 |g year:2017 |g pages:84-96 |g extent:13 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.phrs.2017.07.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 951 | |a AR | ||
| 952 | |d 126 |j 2017 |h 84-96 |g 13 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
z z zz |
|---|---|
| matchkey_str |
zhuzhihongliyuenanyangxinggangpanweisanp:2017----:hrvrinfniacrrgnaoimfaoieadoeaebteylrnccd |
| hierarchy_sort_str |
2017 |
| publishDate |
2017 |
| allfields |
10.1016/j.phrs.2017.07.011 doi GBV00000000000037.pica (DE-627)ELV041064291 (ELSEVIER)S1043-6618(17)30207-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 330 VZ Zhu, Zhihong verfasserin aut The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles 2017 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Display Omitted Chemotherapy Elsevier Docetaxel Elsevier Endocrine therapy Elsevier Nanoparticle drug delivery Elsevier Combination therapy Elsevier Tamoxifen Elsevier Li, Yuenan oth Yang, Xinggang oth Pan, Weisan oth Pan, Hao oth Enthalten in Academic Press Deng, Lixing ELSEVIER Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China 2022 the official journal of the Italian Pharmacological Society London (DE-627)ELV008224951 volume:126 year:2017 pages:84-96 extent:13 https://doi.org/10.1016/j.phrs.2017.07.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 126 2017 84-96 13 045F 610 |
| spelling |
10.1016/j.phrs.2017.07.011 doi GBV00000000000037.pica (DE-627)ELV041064291 (ELSEVIER)S1043-6618(17)30207-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 330 VZ Zhu, Zhihong verfasserin aut The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles 2017 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Display Omitted Chemotherapy Elsevier Docetaxel Elsevier Endocrine therapy Elsevier Nanoparticle drug delivery Elsevier Combination therapy Elsevier Tamoxifen Elsevier Li, Yuenan oth Yang, Xinggang oth Pan, Weisan oth Pan, Hao oth Enthalten in Academic Press Deng, Lixing ELSEVIER Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China 2022 the official journal of the Italian Pharmacological Society London (DE-627)ELV008224951 volume:126 year:2017 pages:84-96 extent:13 https://doi.org/10.1016/j.phrs.2017.07.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 126 2017 84-96 13 045F 610 |
| allfields_unstemmed |
10.1016/j.phrs.2017.07.011 doi GBV00000000000037.pica (DE-627)ELV041064291 (ELSEVIER)S1043-6618(17)30207-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 330 VZ Zhu, Zhihong verfasserin aut The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles 2017 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Display Omitted Chemotherapy Elsevier Docetaxel Elsevier Endocrine therapy Elsevier Nanoparticle drug delivery Elsevier Combination therapy Elsevier Tamoxifen Elsevier Li, Yuenan oth Yang, Xinggang oth Pan, Weisan oth Pan, Hao oth Enthalten in Academic Press Deng, Lixing ELSEVIER Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China 2022 the official journal of the Italian Pharmacological Society London (DE-627)ELV008224951 volume:126 year:2017 pages:84-96 extent:13 https://doi.org/10.1016/j.phrs.2017.07.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 126 2017 84-96 13 045F 610 |
| allfieldsGer |
10.1016/j.phrs.2017.07.011 doi GBV00000000000037.pica (DE-627)ELV041064291 (ELSEVIER)S1043-6618(17)30207-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 330 VZ Zhu, Zhihong verfasserin aut The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles 2017 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Display Omitted Chemotherapy Elsevier Docetaxel Elsevier Endocrine therapy Elsevier Nanoparticle drug delivery Elsevier Combination therapy Elsevier Tamoxifen Elsevier Li, Yuenan oth Yang, Xinggang oth Pan, Weisan oth Pan, Hao oth Enthalten in Academic Press Deng, Lixing ELSEVIER Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China 2022 the official journal of the Italian Pharmacological Society London (DE-627)ELV008224951 volume:126 year:2017 pages:84-96 extent:13 https://doi.org/10.1016/j.phrs.2017.07.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 126 2017 84-96 13 045F 610 |
| allfieldsSound |
10.1016/j.phrs.2017.07.011 doi GBV00000000000037.pica (DE-627)ELV041064291 (ELSEVIER)S1043-6618(17)30207-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 330 VZ Zhu, Zhihong verfasserin aut The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles 2017 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Display Omitted Chemotherapy Elsevier Docetaxel Elsevier Endocrine therapy Elsevier Nanoparticle drug delivery Elsevier Combination therapy Elsevier Tamoxifen Elsevier Li, Yuenan oth Yang, Xinggang oth Pan, Weisan oth Pan, Hao oth Enthalten in Academic Press Deng, Lixing ELSEVIER Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China 2022 the official journal of the Italian Pharmacological Society London (DE-627)ELV008224951 volume:126 year:2017 pages:84-96 extent:13 https://doi.org/10.1016/j.phrs.2017.07.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 126 2017 84-96 13 045F 610 |
| language |
English |
| source |
Enthalten in Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China London volume:126 year:2017 pages:84-96 extent:13 |
| sourceStr |
Enthalten in Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China London volume:126 year:2017 pages:84-96 extent:13 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Chemotherapy Docetaxel Endocrine therapy Nanoparticle drug delivery Combination therapy Tamoxifen |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China |
| authorswithroles_txt_mv |
Zhu, Zhihong @@aut@@ Li, Yuenan @@oth@@ Yang, Xinggang @@oth@@ Pan, Weisan @@oth@@ Pan, Hao @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV008224951 |
| dewey-sort |
3610 |
| id |
ELV041064291 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV041064291</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624082142.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180725s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.phrs.2017.07.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000037.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV041064291</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1043-6618(17)30207-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">330</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zhu, Zhihong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Display Omitted</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Docetaxel</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Endocrine therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nanoparticle drug delivery</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Combination therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tamoxifen</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Yuenan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Xinggang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pan, Weisan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pan, Hao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Academic Press</subfield><subfield code="a">Deng, Lixing ELSEVIER</subfield><subfield code="t">Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China</subfield><subfield code="d">2022</subfield><subfield code="d">the official journal of the Italian Pharmacological Society</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV008224951</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:126</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:84-96</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.phrs.2017.07.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">126</subfield><subfield code="j">2017</subfield><subfield code="h">84-96</subfield><subfield code="g">13</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Zhu, Zhihong |
| spellingShingle |
Zhu, Zhihong ddc 610 ddc 330 Elsevier Chemotherapy Elsevier Docetaxel Elsevier Endocrine therapy Elsevier Nanoparticle drug delivery Elsevier Combination therapy Elsevier Tamoxifen The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles |
| authorStr |
Zhu, Zhihong |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV008224951 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 330 - Economics |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 330 VZ The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles Chemotherapy Elsevier Docetaxel Elsevier Endocrine therapy Elsevier Nanoparticle drug delivery Elsevier Combination therapy Elsevier Tamoxifen Elsevier |
| topic |
ddc 610 ddc 330 Elsevier Chemotherapy Elsevier Docetaxel Elsevier Endocrine therapy Elsevier Nanoparticle drug delivery Elsevier Combination therapy Elsevier Tamoxifen |
| topic_unstemmed |
ddc 610 ddc 330 Elsevier Chemotherapy Elsevier Docetaxel Elsevier Endocrine therapy Elsevier Nanoparticle drug delivery Elsevier Combination therapy Elsevier Tamoxifen |
| topic_browse |
ddc 610 ddc 330 Elsevier Chemotherapy Elsevier Docetaxel Elsevier Endocrine therapy Elsevier Nanoparticle drug delivery Elsevier Combination therapy Elsevier Tamoxifen |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
y l yl x y xy w p wp h p hp |
| hierarchy_parent_title |
Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China |
| hierarchy_parent_id |
ELV008224951 |
| dewey-tens |
610 - Medicine & health 330 - Economics |
| hierarchy_top_title |
Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV008224951 |
| title |
The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles |
| ctrlnum |
(DE-627)ELV041064291 (ELSEVIER)S1043-6618(17)30207-4 |
| title_full |
The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles |
| author_sort |
Zhu, Zhihong |
| journal |
Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China |
| journalStr |
Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
84 |
| author_browse |
Zhu, Zhihong |
| container_volume |
126 |
| physical |
13 |
| class |
610 610 DE-600 330 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Zhu, Zhihong |
| doi_str_mv |
10.1016/j.phrs.2017.07.011 |
| dewey-full |
610 330 |
| title_sort |
reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles |
| title_auth |
The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles |
| abstract |
Display Omitted |
| abstractGer |
Display Omitted |
| abstract_unstemmed |
Display Omitted |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles |
| url |
https://doi.org/10.1016/j.phrs.2017.07.011 |
| remote_bool |
true |
| author2 |
Li, Yuenan Yang, Xinggang Pan, Weisan Pan, Hao |
| author2Str |
Li, Yuenan Yang, Xinggang Pan, Weisan Pan, Hao |
| ppnlink |
ELV008224951 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1016/j.phrs.2017.07.011 |
| up_date |
2024-07-06T19:07:41.347Z |
| _version_ |
1803857807379791872 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV041064291</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624082142.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180725s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.phrs.2017.07.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000037.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV041064291</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1043-6618(17)30207-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">330</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zhu, Zhihong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Display Omitted</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Docetaxel</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Endocrine therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nanoparticle drug delivery</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Combination therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tamoxifen</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Yuenan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Xinggang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pan, Weisan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pan, Hao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Academic Press</subfield><subfield code="a">Deng, Lixing ELSEVIER</subfield><subfield code="t">Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China</subfield><subfield code="d">2022</subfield><subfield code="d">the official journal of the Italian Pharmacological Society</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV008224951</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:126</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:84-96</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.phrs.2017.07.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">126</subfield><subfield code="j">2017</subfield><subfield code="h">84-96</subfield><subfield code="g">13</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4003763 |